Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > The IPF and Chronic Cough study is now on the back burner.

<< Previous

Bullboard Posts

Next >>

Comment by BlaineBorgon Jun 18, 2021 8:52pm

133 Views

Post# 33415830

RE:RE:RE:RE:RE:The IPF and Chronic Cough study is now on the back burner.

It can't get any worse because they don't know when they will achieve full enrollment. The timeline is already costing us big-time while another bs pp is on the horizon. If he cant land some government handout money or a partnership deal asap then I'm of the belief the business model and/or trial designs are flawed. They are simply too small to ever get to statistical significance and they knew it going in with the covid study. Now it's a backtrack as if covid was never pushed to the front of the pipeline. BB

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland